AMDA and ASCP Join Forces for Guidance on Monoclonal Antibody Treatments for COVID-19 in Long-Term Care

Several monoclonal antibodies (MAbs) received emergency use authorization from the U.S. Food and Drug Administration for the treatment of mild to moderate COVID-19 infection in adults who have had positive results in direct SARS-CoV-2 viral testing and those at high risk for progressing to severe COVID-19 and/or hospitalization. AMDA – The Society for Post-Acute and Long-Term Care Medicine and the American Society of Consultant Pharmacists (ASCP) recently collaborated on a readiness document, “Monoclonal Antibody Treatments in Senior Care Environments,” to help facilitate the safe use of these therapies and enable facilities to have appropriate access.